BEIJING BEILU PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.93 CNY | -2.18% |
|
-1.99% | -30.76% |
| Sales 2022 | 766M 106M | Sales 2023 | 891M 123M | Capitalization | 3.5B 484M |
|---|---|---|---|---|---|
| Net income 2022 | 11M 1.52M | Net income 2023 | -71M -9.8M | EV / Sales 2022 | 4.03 x |
| Net cash position 2022 | 120M 16.57M | Net Debt 2023 | 42.28M 5.84M | EV / Sales 2023 | 3.98 x |
| P/E ratio 2022 |
326
x | P/E ratio 2023 |
-47.5
x | Employees | 952 |
| Yield 2022 |
1.07% | Yield 2023 |
-
| Free-Float | 66.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.18% | ||
| 1 week | -1.99% | ||
| Current month | -0.20% | ||
| 1 month | +13.07% | ||
| 3 months | +4.45% | ||
| 6 months | -36.47% | ||
| Current year | -30.76% |
1 week
4.89
5.16
1 month
4.485.60
Current year
3.587.23
1 year
3.588.93
3 years
3.5810.56
5 years
3.5814.08
10 years
3.5844.39
| Managers | Title | Age | Since |
|---|---|---|---|
Xu Wang
CEO | Chief Executive Officer | 40 | 10-12-31 |
Ni Zeng
DFI | Director of Finance/CFO | 32 | 18-05-31 |
Ze Hui Shao
BRD | Director/Board Member | 44 | 18-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qing Xiang
BRD | Director/Board Member | 53 | 07-04-24 |
Wei Jiang
BRD | Director/Board Member | 51 | 22-04-19 |
Gen Chang Zheng
BRD | Director/Board Member | 55 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 4.93 | -2.18% | 6 168 600 |
| 24-05-22 | 5.04 | +0.20% | 4,785,100 |
| 24-05-21 | 5.03 | -0.98% | 5,698,400 |
| 24-05-20 | 5.08 | -0.39% | 6,230,150 |
| 24-05-17 | 5.1 | +0.39% | 5,838,900 |
End-of-day quote Shenzhen S.E., May 22, 2024
More quotes
Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -30.76% | 342M | |
| +38.27% | 723B | |
| +34.28% | 595B | |
| -4.30% | 369B | |
| +20.19% | 332B | |
| +2.88% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.03% | 168B |
- Stock Market
- Equities
- 300016 Stock
